IA和MA方案治疗急性髓系白血病临床观察  

The response of acute myeloid leukemia(AML) to IA and MA regimen in the treatment.

作　　者：李雪芬 程永贵[2] 陆赛君 金丽 

机构地区：[1]浙江省象山县第一人民医院血液科,315700 [2]吉林省人民医院检验科,130021

出　　处：《浙江临床医学》2002年第7期498-499,共2页Zhejiang Clinical Medical Journal

摘　　要：目的 评价IA和MA方案在治疗急性髓系白血病(AML)中的临床价值。方法 用t检验和卡方检验比较两组治疗方案的疗效及不良反应。结果 ①IA和MA方案的完全缓解 (CR)率分别为84.2 %和61.9 %,有显著性差异 (p<0.05) ;②两组方案治疗早期死亡率分别为7.9 %和9.5 %,无显著性差异 ( p>0.05) ;③IA方案达CR平均疗程为1.2较MA方案1.5疗程短 ;④两组方案治疗后不良反应有所差异 ,但均可耐受。结论 在AML治疗中 ,IA方案优于MA方案 ,值得临床选用。Objective To evaluate the response of acute myeloid leukemia(AML)to IA and MA regimen in the treatment. Methods To compare the therapeutic effect and toxicities of two groups of AML patients who were treated with IA or MA regimen. Results ①Complete remission(CR)rate was achieved 84.2% in the IA group and 61.9% in the MA group(p<0.05).②Early mortality rate was 7.9% in IA group and 9.5% in MA group, there was no significant difference between two groups(p>0.05).③Average course between receiving chemotherapies to achieve CR was 1.2 in IA group, which was shorter than 1.5 in MA group. ④There was a little difference in toxicities and side effects between two groups. All patients could tolerate therapy well. Conclusion The IA program was found better than MA program, should be the first regimen selected for the treatment of AML.

关 键 词：IA方案 MA方案 急性髓系白血病 化学疗法 临床观察 

分 类 号：R733.71[医药卫生—肿瘤]